Accelerator-based BNCT for patients with recurrent glioblastoma: a multicenter phase II study.

Shinji KawabataMinoru SuzukiKatsumi Hirose Hiroki TanakaTakahiro KatoHiromi Goto Yoshitaka Narita Shin-Ichi Miyatake

Published in: Neuro-oncology advances (2021)

AB-BNCT demonstrated acceptable safety and prolonged survival for recurrent MG. AB-BNCT may increase the risk of brain edema due to re-irradiation for recurrent MG; however, this appears to be controlled well with bevacizumab.

Keyphrases

phase ii study
open label
locally advanced
clinical trial
squamous cell carcinoma
randomized controlled trial
resting state
multiple sclerosis
radiation therapy
study protocol
metastatic colorectal cancer